The first generation of biological drugs in psoriasis consists of the anti-TNF agents (TNF inhibitors; TNFi), incorporating four mAbs (Infliximab, Adalimumab, Certolizumab Pegol, Golimumab) and a single chimeric protein (Etanercept). The gene discussed is TNF; the disease is psoriasis.